HomeCompareINFI vs MRK

INFI vs MRK: Dividend Comparison 2026

INFI yields 25000.00% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 INFI wins by $481652020747103174656.00M in total portfolio value
10 years
INFI
INFI
● Live price
25000.00%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$481652020747103174656.00M
Annual income
$477,891,679,681,809,340,000,000,000.00
Full INFI calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — INFI vs MRK

📍 INFI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodINFIMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, INFI + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
INFI pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

INFI
Annual income on $10K today (after 15% tax)
$2,125,000.00/yr
After 10yr DRIP, annual income (after tax)
$406,207,927,729,537,960,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, INFI beats the other by $406,207,927,729,537,960,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of INFI + MRK for your $10,000?

INFI: 50%MRK: 50%
100% MRK50/50100% INFI
Portfolio after 10yr
$240826010373551587328.00M
Annual income
$238,945,839,840,904,670,000,000,000.00/yr
Blended yield
99.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

INFI
Analyst Ratings
8
Buy
9
Hold
Consensus: Hold
Altman Z
-63.6
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

INFI buys
0
MRK buys
0
No recent congressional trades found for INFI or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricINFIMRK
Forward yield25000.00%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$481652020747103174656.00M$56.8K
Annual income after 10y$477,891,679,681,809,340,000,000,000.00$9,798.13
Total dividends collected$481404327977371041792.00M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: INFI vs MRK ($10,000, DRIP)

YearINFI PortfolioINFI Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$2,510,700$2,500,000.00$11,206$366.19+$2.50MINFI
2$589,298,599$586,612,149.53$12,650$502.35+$589.29MINFI
3$129,309,604,119$128,679,054,618.90$14,407$694.19+$129309.59MINFI
4$26,527,150,102,459$26,388,788,826,051.22$16,585$967.82+$26527150.09MINFI
5$5,087,743,001,217,608$5,059,358,950,607,977.00$19,342$1,363.89+$5087743001.20MINFI
6$912,316,496,169,531,500$906,872,611,158,228,600.00$22,913$1,947.19+$912316496169.51MINFI
7$152,954,929,371,424,950,000$151,978,750,720,523,570,000.00$27,662$2,823.89+$152954929371424.91MINFI
8$23,976,822,470,935,107,000,000$23,813,160,696,507,682,000,000.00$34,159$4,173.35+$23976822470935108.00MINFI
9$3,514,337,444,199,857,700,000,000$3,488,682,244,155,957,000,000,000.00$43,337$6,308.80+$3514337444199857664.00MINFI
10$481,652,020,747,103,200,000,000,000$477,891,679,681,809,340,000,000,000.00$56,776$9,798.13+$481652020747103174656.00MINFI

INFI vs MRK: Complete Analysis 2026

INFIStock

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.

Full INFI Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this INFI vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

INFI vs SCHDINFI vs JEPIINFI vs OINFI vs KOINFI vs MAININFI vs JNJINFI vs ABBVINFI vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.